ApiFix Receives FDA Regulatory Approval

Misgav, Israel, 28 August 2019 –The Trendlines Group Ltd. ("The Trendlines Group" or "Trendlines") (SGX: 42T; OTCQX: TRNLY), is pleased to announce that its portfolio company ApiFix Ltd., ("ApiFix") a leading scoliosis correction company and one of Trendlines' ten most valuable companies, received regulatory approval from the United States Food and Drug Administration ("FDA") to commercialize its MID-C System for motion-preserving deformity treatment of progressive adolescent idiopathic scoliosis ("AIS"). The FDA announced its approval of ApiFix's MID-C System via social media.

AIS is the most common type of scoliosis and affects 2%-3% of the population between ages 10 to 21. Generally, AIS curves progress during an adolescent's rapid growth period and, while most curves slow their progression significantly at the time of skeletal maturity, some deformities, especially curves greater than 50°, continue to progress during adulthood.

FDA approval will enable ApiFix to begin selling its device in the United States. The MID-C System has had CE approval in Europe since December 2012 and more than 300 surgical procedures have been completed, including a number of implantations in Singapore.

In a press release by the company, ApiFix CEO, Paul Mraz said, "FDA approval of ApiFix's MID-C system is a significant achievement for our company….it makes a notable treatment advancement available for patients and their families who want FDA-approved alternatives to permanent spinal fusion. Our MID-C System addresses a significant unmet clinical need for a motion-preserving alternative to spinal fusion and is a viable treatment option for progressive scoliosis in a select group of AIS patients."

Chairman and CEO of The Trendlines Group, Todd Dollinger commented: "We are extremely proud of this achievement by ApiFix. Since the establishment of ApiFix in 2011, we have identified strongly with the company's mission of positively impacting the lives of young patients with scoliosis. This will now be possible in the United States, following the company's clinical successes in other countries around the world."

About The Trendlines Group Ltd.

Trendlines is an innovation commercialization company that invents, discovers, invests in, and incubates innovation-based medical and agricultural technologies to fulfill its mission to improve the human condition. As intensely hands-on investors, Trendlines is involved in all aspects of its portfolio companies from technology development to business building. Trendlines' shares are traded on the Singapore Stock Exchange (SGX: 42T) and in the United States as an American Depositary Receipt (ADR) on the OTCQX (OTCQX: TRNLY).

****

Investor Contact Information

Israel:
Shira Zimmerman, The Trendlines Group
shira@trendlines.com
Tel: +972.72.260.7000

Singapore and China:
Reyna MEI, Financial PR
reyna@financialpr.com.sg
Tel: +65.6438.2990

This press release has been prepared by the Company and its contents have been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor") in accordance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalist.

This press release has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms. Jennifer Tan, Associate Director, Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg).